US EditionPublished • loading... • Updated
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
Summary by Missoulian
21 Articles
21 Articles
Montana Standard+20 Reposted by 20 other sources
D3 Bio to Showcase Its Innovative KRAS Pipeline at AACR 2026, Including an Oral Presentation at Clinical Plenary Session
SHANGHAI, March 19, 2026 /PRNewswire/ -- D3 Bio Inc, a global clinical-stage biotechnology company focused on developing transformative oncology therapeutics, is pleased to announce that five abstracts have been accepted for presentation at the upcoming American Association for Cancer Research…
Coverage Details
Total News Sources21
Leaning Left1Leaning Right1Center8Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
C 80%
Factuality
To view factuality data please Upgrade to Premium
